Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immuneering (IMRX) Consolidated Net Income (2020 - 2026)

Immuneering's Consolidated Net Income history spans 7 years, with the latest figure at -$14.0 million for Q1 2026.

  • On a quarterly basis, Consolidated Net Income rose 7.12% to -$14.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$55.3 million, a 10.87% increase, with the full-year FY2025 number at -$56.3 million, up 8.36% from a year prior.
  • Consolidated Net Income came in at -$14.0 million for Q1 2026, down from -$11.9 million in the prior quarter.
  • The five-year high for Consolidated Net Income was -$11.5 million in Q2 2022, with the low at -$18.1 million in Q4 2024.
  • Historically, Consolidated Net Income has averaged -$14.0 million across 5 years, with a median of -$14.0 million in 2026.
  • Biggest five-year swings in Consolidated Net Income: crashed 105.36% in 2022 and later surged 34.46% in 2025.
  • Year by year, Consolidated Net Income stood at -$13.5 million in 2022, then decreased by 15.44% to -$15.5 million in 2023, then dropped by 16.69% to -$18.1 million in 2024, then surged by 34.46% to -$11.9 million in 2025, then decreased by 17.52% to -$14.0 million in 2026.
  • Business Quant data shows Consolidated Net Income for IMRX at -$14.0 million in Q1 2026, -$11.9 million in Q4 2025, and -$15.0 million in Q3 2025.